CA2917811C - Derivatives of n-urea substituted amino acids as formyl peptide receptor modulators - Google Patents

Derivatives of n-urea substituted amino acids as formyl peptide receptor modulators Download PDF

Info

Publication number
CA2917811C
CA2917811C CA2917811A CA2917811A CA2917811C CA 2917811 C CA2917811 C CA 2917811C CA 2917811 A CA2917811 A CA 2917811A CA 2917811 A CA2917811 A CA 2917811A CA 2917811 C CA2917811 C CA 2917811C
Authority
CA
Canada
Prior art keywords
optionally substituted
alkyl
amino
cycloalkyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2917811A
Other languages
English (en)
French (fr)
Other versions
CA2917811A1 (en
Inventor
Richard L. Beard
Tien T. Duong
John E. Donello
Veena Viswanath
Michael E. Garst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CA2917811A1 publication Critical patent/CA2917811A1/en
Application granted granted Critical
Publication of CA2917811C publication Critical patent/CA2917811C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2917811A 2013-07-16 2014-07-10 Derivatives of n-urea substituted amino acids as formyl peptide receptor modulators Active CA2917811C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361846787P 2013-07-16 2013-07-16
US61/846,787 2013-07-16
PCT/US2014/046203 WO2015009545A1 (en) 2013-07-16 2014-07-10 Derivatives of n-urea substituted amino acids as formyl peptide receptor modulators

Publications (2)

Publication Number Publication Date
CA2917811A1 CA2917811A1 (en) 2015-01-22
CA2917811C true CA2917811C (en) 2021-08-31

Family

ID=51230227

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2917811A Active CA2917811C (en) 2013-07-16 2014-07-10 Derivatives of n-urea substituted amino acids as formyl peptide receptor modulators

Country Status (11)

Country Link
US (1) US9428549B2 (enExample)
EP (1) EP3022174B1 (enExample)
JP (1) JP6653253B2 (enExample)
KR (1) KR102313757B1 (enExample)
CN (1) CN105377814B (enExample)
AU (1) AU2014290618B2 (enExample)
CA (1) CA2917811C (enExample)
DK (1) DK3022174T3 (enExample)
ES (1) ES2708571T3 (enExample)
RU (1) RU2696581C2 (enExample)
WO (1) WO2015009545A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE040145T2 (hu) 2011-10-26 2019-02-28 Allergan Inc N-karbamid szubsztituált aminosavak amid származékai mint formilpeptidszerû receptor 1 (FPRL1) receptormodulátorok
AU2014226001B2 (en) 2013-03-06 2018-12-06 Allergan, Inc. Use of agonists of Formyl peptide receptor 2 for treating dermatological diseases
BR112016011417A8 (pt) 2013-11-21 2020-05-05 Allergan Inc derivados de fenilcarbamatos como moduladores do receptor de formil peptídeo, composição farmacêutica, e seus usos
EP3305763B1 (en) 2013-11-28 2019-07-24 Kyorin Pharmaceutical Co., Ltd. Deuterated or isotopically labeled urea derivatives or pharmacologically acceptable salts thereof useful as fprl-1 agonists
US9663457B2 (en) 2014-04-09 2017-05-30 Allergan, Inc. Carbamoyl hydrazine derivatives as formyl peptide modulators
KR20170005121A (ko) 2014-05-21 2017-01-11 알러간, 인코포레이티드 폼일 펩타이드 수용체 조절제로서의 이미다졸 유도체
AU2016266190A1 (en) 2015-05-27 2018-01-18 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
WO2016189877A1 (en) 2015-05-27 2016-12-01 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
TW201718473A (zh) * 2015-08-05 2017-06-01 歐樂根公司 作為甲醯肽受體１（ｆｐｒ１）選擇性促效劑之苯基脲類似物
WO2019173182A1 (en) 2018-03-05 2019-09-12 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2533210A1 (fr) 1982-09-17 1984-03-23 Lyon I Universite Claude Edulcorants de synthese
US5284828A (en) 1990-05-14 1994-02-08 Fujisawa Pharmaceutical Co. Ltd. Peptide compound and its preparation
JP3387948B2 (ja) 1992-12-04 2003-03-17 富山化学工業株式会社 新規なフェニルアラニン誘導体またはその塩
US20030009022A1 (en) * 1993-03-31 2003-01-09 Cadus Pharmaceutical Corporation Methods and compositions for identifying receptor effectors
PT739903E (pt) * 1994-02-09 2002-05-31 Shionogi & Co Derivado carbamoilmetilureia
JP2968842B2 (ja) * 1994-02-09 1999-11-02 塩野義製薬株式会社 カルバモイルメチルウレア誘導体
US6423689B1 (en) * 1997-12-22 2002-07-23 Warner-Lambert Company Peptidyl calcium channel blockers
US6548637B1 (en) * 1998-06-18 2003-04-15 Sepracor, Inc. Ligands for opioid receptors
JP2005536187A (ja) * 2002-04-03 2005-12-02 バイエル・ヘルスケア・アクチェンゲゼルシャフト Ｎ−ホルミルペプチド受容体様１（ｆｐｒｌ１）に関連する疾患の診断および治療
WO2005047899A2 (en) 2003-11-07 2005-05-26 Acadia Pharmaceuticals Inc. Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation
JP5510945B2 (ja) * 2009-05-18 2014-06-04 アクテリオン ファーマシューティカルズ リミテッド Ａｌｘ受容体及び／又はｆｐｒｌ２アゴニストとしての架橋スピロ［２．４］ヘプタン誘導体
AU2011336973A1 (en) * 2010-12-03 2013-07-11 Allergan, Inc. Pharmaceutical compositions comprising 3,4- dihydroisoquinolin-2(1 H)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity
HUE040145T2 (hu) 2011-10-26 2019-02-28 Allergan Inc N-karbamid szubsztituált aminosavak amid származékai mint formilpeptidszerû receptor 1 (FPRL1) receptormodulátorok
US8541577B2 (en) * 2011-11-10 2013-09-24 Allergan, Inc. Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators
US8735622B2 (en) * 2011-11-30 2014-05-27 The Regents Of The University Of Colorado, A Body Corporate Histone demethylase inhibitors and methods for using the same
EP2964213B1 (en) * 2013-03-06 2020-11-04 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
AU2014226001B2 (en) * 2013-03-06 2018-12-06 Allergan, Inc. Use of agonists of Formyl peptide receptor 2 for treating dermatological diseases

Also Published As

Publication number Publication date
US20150025021A1 (en) 2015-01-22
CN105377814B (zh) 2018-04-03
WO2015009545A1 (en) 2015-01-22
EP3022174B1 (en) 2018-09-05
JP6653253B2 (ja) 2020-02-26
EP3022174A1 (en) 2016-05-25
RU2016104844A (ru) 2017-08-21
CN105377814A (zh) 2016-03-02
CA2917811A1 (en) 2015-01-22
DK3022174T3 (da) 2019-01-02
US9428549B2 (en) 2016-08-30
ES2708571T3 (es) 2019-04-10
JP2016529235A (ja) 2016-09-23
AU2014290618A1 (en) 2016-02-18
KR20160031007A (ko) 2016-03-21
AU2014290618B2 (en) 2018-04-05
RU2696581C2 (ru) 2019-08-05
KR102313757B1 (ko) 2021-10-18

Similar Documents

Publication Publication Date Title
AU2012329098B2 (en) Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
AU2012336013C1 (en) Aryl urea derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
AU2014290618B2 (en) Derivatives of N-urea substituted amino acids as formyl peptide receptor modulators
EP2838887B1 (en) (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
WO2015042071A1 (en) Diphenyl urea derivatives as formyl peptide receptor modulators
US9868700B2 (en) Carbamoyl hydrazine derivatives as formyl peptide modulators
AU2021261917A1 (en) Phenyl urea derivatives as N-formyl peptide receptor modulators
HK1225012A1 (en) Derivatives of n-urea substituted amino acids as formyl peptide receptor modulators
HK1225012B (en) Derivatives of n-urea substituted amino acids as formyl peptide receptor modulators
HK1228885A1 (en) Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators
HK1199622B (en) Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators
HK1228885A (en) Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190705

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251211

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260313

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260313

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260325

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260420